At some point there will be a boom biotechnology stocks. They haven't done much in the past ten years. I believe IBB will pass 250 within the decade. However, if the market remains stable, without any 20%+ corrections, I think IBB hits 250 to 300 in the next year
IBB looks to be in a Wyckoff Redistribution phase, with UTAD emerging currently. On a larger time frame, looks as though a weekly H&S patter forming with the re-distribution section acting as the right shoulder. My price target is $57, in line with the 1.618 fib extension.
🔸Hello guys, today let's review 2daily chart for IBB . Entering re-accumulation stage now, expecting range bound trading during autumn time season. Range defined by range highs set at 135 usd and range lows at 117 usd. 🔸Similar fractal observed in 2018/2019. Faded into range after heavy spike, re-accumulation then 50% pump later during spring 2020. 🔸Recommended...
Clean bottoming pattern formed as well as clean shifting of momentum here Look for the bull flag breakout of the head and shoulders for 10-15% upside here
Biotech was one of the first sectors in the market to show relative strength and catch some bids throughout the June bottoming process. IBB rallied 20% off the lows and then proceeded to consolidate sideways for 3 weeks. This Wednesday, IBB broke out of that consolidation with a gap up on heavy volume and is now finding more follow-through. Keep an eye on the...
IBB bounced from the green pandemic support zone last March but have came back down to retest this zone. IBB has found support exactly on my GANN FAN line for several times before it breaks down & retested the violet downtrend line & bounced, making a reversal with a long hammer candle. IBB may close today above my GANN FAN line support confirming reversal ....
MRNA is heading higher, don't sell, hold it until 520, we may get it by Dec 20th, 2021, next resistance is 376.
Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB D4: TOPPED OUT // correction looming // SHORT...
Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates IBB D2: TOPPED OUT // correction looming // SHORT...
All charts and comments are for entertainment and educational purposes only. For Trading Advice, seek out a professional.
Good afternoon. I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company. Summary Technical analysis On the chart, we can see the imminent completion of corrective wave 2 and the appearance of impulse wave 3. ...
Good afternoon. I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company. Summary: Technical analysis: On the chart, we can see the completion of corrective wave 2 and the emergence of impulse wave 3. According to...
The major indices like AMEX:SPY NASDAQ:QQQ have held up well despite talks of the delta variant though peeling back a few layers shows that there are underlying concerns. Many biotech, cloud software, and stay at home names are showing strong chart patterns that are poised to move higher. Among those names are NASDAQ:IBB NASDAQ:GILD NASDAQ:ZM CRM and ...
Greetings Summary: Fundamental Analysis: Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021 In April 2021, the Company expects to initiate a randomized, proof of...
Greetings Summary: Fundamental Analysis: Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative.Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies Fluidigm is a leader in mass cytometry....
The target level is around 166.